Stock News

Weiss Asset Management LP Has Lifted Its Ani Pharmaceuticals (ANIP) Position by $5.80 Million; Market Valuation Declined; Intercontinental Exchange (ICE) Shareholder Balyasny Asset Management Trimmed Stake by $9.08 Million

Andrew Weiss increased its stake in Ani Pharmaceuticals Inc (ANIP) by 255.74% based on its latest 2017Q3 regulatory filing with the SEC. Weiss Asset Management Lp bought 111,493 shares as the company’s stock declined 26.94% while stock markets rallied. The hedge fund run by Andrew Weiss held 155,089 shares of the health care company at the end of 2017Q3, valued at $8.14M, up from 43,596 at the end of the previous reported quarter. Weiss Asset Management Lp who had been investing in Ani Pharmaceuticals Inc for a number of months, seems to be bullish on the $682.40M market cap company. The stock increased 0.34% or $0.2 during the last trading session, reaching $58.61. About 19,614 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has declined 0.02% since February 13, 2017 and is downtrending. It has underperformed by 16.72% the S&P500.

Dmitry Balyasny decreased its stake in Intercontinental Exchange Inc (ICE) by 80.9% based on its latest 2017Q3 regulatory filing with the SEC. Balyasny Asset Management Llc sold 133,458 shares as the company’s stock rose 1.58% with the market. The hedge fund run by Dmitry Balyasny held 31,513 shares of the investment bankers and brokers and service company at the end of 2017Q3, valued at $2.17M, down from 164,971 at the end of the previous reported quarter. Balyasny Asset Management Llc who had been investing in Intercontinental Exchange Inc for a number of months, seems to be less bullish one the $39.97B market cap company. The stock increased 0.07% or $0.05 during the last trading session, reaching $68.65. About 834,237 shares traded. Intercontinental Exchange, Inc. (NYSE:ICE) has risen 13.80% since February 13, 2017 and is uptrending. It has underperformed by 2.90% the S&P500.

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma had 19 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was upgraded by Oppenheimer on Tuesday, July 19 to “Perform”. As per Thursday, June 23, the company rating was initiated by Raymond James. The stock has “Hold” rating by Standpoint Research on Tuesday, May 24. Standpoint Research initiated ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on Friday, November 13 with “Buy” rating. TH Capital upgraded the shares of ANIP in report on Monday, September 28 to “Buy” rating. The rating was maintained by Oppenheimer with “Outperform” on Friday, August 5. TH Capital maintained the shares of ANIP in report on Tuesday, August 4 with “Neutral” rating. The rating was maintained by Roth Capital with “Hold” on Thursday, November 2. The firm has “Buy” rating by Canaccord Genuity given on Thursday, December 7. Canaccord Genuity maintained ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) rating on Wednesday, August 9. Canaccord Genuity has “Buy” rating and $6000 target.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.63, from 1.06 in 2017Q2. It is positive, as 16 investors sold ANIP shares while 26 reduced holdings. 22 funds opened positions while 49 raised stakes. 6.31 million shares or 1.29% less from 6.39 million shares in 2017Q2 were reported. Raymond James Assocs reported 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Blackrock holds 1.27M shares. Dimensional Fund Ltd Partnership accumulated 0.01% or 424,797 shares. Etrade Cap Limited Co holds 0.05% or 24,425 shares in its portfolio. Thrivent Fincl For Lutherans invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Manufacturers Life The invested in 6,374 shares. Thomson Horstmann And Bryant Inc has invested 0.11% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). The New York-based Consonance Limited Partnership has invested 0.83% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Comerica Commercial Bank reported 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Moreover, Raymond James Financial Advsrs Inc has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 10,023 shares. Nationwide Fund Advisors reported 5,287 shares or 0% of all its holdings. Ls Advisors Ltd Liability reported 0.01% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). 26,915 were accumulated by Globeflex L P. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 235 shares. Cadence Capital Mgmt Ltd, Massachusetts-based fund reported 33,402 shares.

Weiss Asset Management Lp, which manages about $1.80B and $901.47 million US Long portfolio, decreased its stake in Allergan Plc by 260,062 shares to 5,438 shares, valued at $1.12M in 2017Q3, according to the filing. It also reduced its holding in Sprott Physical Gold Trust (PHYS) by 90,769 shares in the quarter, leaving it with 58,965 shares, and cut its stake in Lam Research Corp (Prn).

Balyasny Asset Management Llc, which manages about $14.49 billion and $25.52B US Long portfolio, upped its stake in Gramercy Property Trust by 636,853 shares to 1.08M shares, valued at $32.55 million in 2017Q3, according to the filing. It also increased its holding in Cimarex Energy Co (NYSE:XEC) by 5,879 shares in the quarter, for a total of 9,169 shares, and has risen its stake in Hcp Inc (NYSE:HCP).

Leave a Reply

Your email address will not be published. Required fields are marked *